1-804-709-0144
ichip-hi-edit

iCHIP® Platform

ImmunArray’s iCHIP® technology mines the information stored in the immune system repertoires in order to shed light on an individual’s specific immune profile.

Learn More

iCHIP intensity

SLE-key®

SLE-key® is a molecular diagnostic test developed by ImmunArray to support a physician’s ability to rule-out a diagnosis of Systemic Lupus Erythematosus (SLE).

Learn More

TBI Program

Immunarray® is developing a series of assays and multiplex tests to assist in the diagnosis and prognosis of Brain Injury, in both acute (TBI) and chronic phases.

Learn More

See Us At

2017 United Rheumatology National Meeting

October 20 – 21, 2017
Hyatt Regency Orlando, Orlando, FL

Read More

2017 American College of Rheumatology Meeting

Monday, November 6, 2017; 9:00 AM – 11:00 AM

Poster Presentation: “The Autoimmune Discovery iCHIP Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)”

Read More

2017 American College of Rheumatology Meeting

Monday, November 6, 2017; 4:30 PM – 6:00 PM

Oral Presentation: “The SLE-Key ® Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity”

Read More
fan

Recent News & Events

ImmunArray Enters Partnership with Kindstar Global

Alliance with China-based diagnostic company to support joint clinical studies and prepare for diagnostic product introduction in Chinese markets

Richmond, VA., July 10, 2017 – ImmunArray, a privately held molecular device company dedicated to the development of novel, blood-based in vitro diagnostic tests, and Kindstar Global Co., Ltd., a specialty clinical testing company based in Wuhan, China with locations throughout mainland China, have forged a partnership involving shared clinical studies and the launch of ImmunArray’s lupus rule-out test in China as the initial product offering.

Read More

Quanterix and ImmunArray Teaming Up to Address Neurodegenerative Disease

Quanterix gains access to ImmunArray brain injury biomarker portfolio and ImmunArray gains access to Quanterix state of the art digital biomarker technology

Read More

ImmunArray Expanding Research and Clinical Momentum on TBI Front

Molecular diagnostic company’s research into blood-based diagnosis of traumatic brain injury presented at national conferences

 Richmond, Va., July 18, 2016 – Clinical research into ways in which blood-based biomarkers can provide precise and timely diagnosis of traumatic brain injury (TBI) is leading to encouraging results, with some studies resulting in a diagnosis with more than 95 percent sensitivity and specificity.

Read More
our-story-crop

Talk to Us

Welcome!

We are a clinically driven company guided by leadership physician input at each stage of our development. We welcome questions and open discussions, and look forward to continuing to work with our collaborators and partners around the globe.

Read More